- Home
- Products
Rezlidhia (Olutasidenib)
Rezlidhia (Olutasidenib)
- Medicine Name: Rezlidhia
- Generic Name: Olutasidenib
- Dosage Form & Strength: Capsules, 150 mg
- Manufactured By: Rigel and Forma Therapeutics, Inc.
Rezlidhia (olutasidenib) is a targeted therapy indicated for adult patients diagnosed with relapsed or refractory Acute Myeloid Leukemia (AML) harboring IDH1 mutations. It works by inhibiting the isocitrate dehydrogenase-1 (IDH1) enzyme involved in abnormal cell growth in AML.
Dosage Guidelines:
The usual recommended dose is 150 mg orally, twice daily. Capsules should be taken on an empty stomach—either 1 hour before or 2 hours after a meal—at the same time each day. Avoid taking a second dose within 8 hours. Do not crush or chew the capsule; swallow whole.
If a dose is missed or vomited, skip that dose and continue with the next scheduled dose. Maintain at least an 8-hour gap between doses. Treatment may continue for at least 6 months if no disease progression or severe side effects are noted.
Liver Monitoring: Regularly monitor liver enzymes and blood chemistry before and during treatment. Rezlidhia can lead to liver toxicity marked by increased AST, ALT, or bilirubin levels.
Differentiation Syndrome: This potentially life-threatening condition may occur. If suspected, stop treatment temporarily and begin corticosteroids (e.g., dexamethasone 10 mg IV every 12 hours) for a minimum of 3 days.
Pregnancy & Breastfeeding: This medication may cause harm to an unborn child. Avoid use during pregnancy. Do not breastfeed while on treatment and for at least 14 days after the last dose.
Hematologic Monitoring: Monitor blood counts weekly for the first two months, then biweekly in the third month, followed by monthly reviews.
To Import Rezlidhia into India, patients require:
- A valid prescription from a certified medical practitioner
- Diagnostic test reports
- Government-issued patient ID proof
Order Confirmation:
Orders are processed only upon receipt of a valid prescription and an import permit (if required by regulatory authorities).
Availability in India:
Rezlidhia (Olutasidenib) is not yet widely available in India. GlobalRareMeds facilitates access through legally authorized Named Patient Import programs. Availability may depend on stock from certified sources in the US, Canada, Europe, or Australia.
GlobalRareMeds specializes in sourcing hard-to-access medications like Rezlidhia for cancer treatment. We procure from verified international pharmaceutical suppliers and ensure global quality standards.
All orders are fulfilled from our center in Ambernath, Thane District, after proper documentation is submitted. Delivery is arranged directly to the patient or prescribing doctor across major Indian cities, including Mumbai, Delhi, Bengaluru, Hyderabad, and Chennai.
For assistance, contact us at:
📧 info@globalraremeds.com
📞 +91-99675 15602
📱 WhatsApp: +91-99675 15602
What is the generic name for Rezlidhia?
Olutasidenib is the generic name for the brand Rezlidhia.
Who manufactures Rezlidhia?
It is manufactured by Rigel and Forma Therapeutics, Inc.
Is Rezlidhia FDA approved?
Yes, Rezlidhia received FDA approval on December 1, 2022.
What is the available strength and form of Rezlidhia?
Rezlidhia is available as 150 mg oral capsules.
Where can I get Rezlidhia in India?
Rezlidhia can be sourced in India through GlobalRareMeds upon submission of a valid prescription and regulatory approvals, if applicable.
What are common side effects?
Patients may experience fatigue, rash, nausea, joint pain, fever, constipation, diarrhea, mouth sores, and shortness of breath.
What are the storage guidelines?
Store at 20°C–25°C (68°F–77°F). Temperature excursions between 15°C–30°C (59°F–86°F) are acceptable.
Is it legal and safe to import Rezlidhia to India?
Yes, GlobalRareMeds helps patients legally import this medicine under the Named Patient Import program, following due regulatory compliance.
Contact Patient Support
If you have questions about your order, need assistance with documentation, or require support with medicine availability, our GlobalRareMeds Patient Support Team is here to help. We aim to respond within 24 hours, Monday to Friday, between 9:00 AM and 10:00 AM IST.
info@globalraremeds.com
Phone
+91 99675 15602
+91 99675 15602
Disclaimer
All trademarks, brands, and product names featured on this website are the property of their respective owners. GlobalRareMeds does not claim ownership or affiliation unless explicitly stated. Our role is to provide reliable and transparent access to difficult-to-source medicines through named-patient import services, based on valid prescriptions and legal requirements.
The product-related content on this website is shared to the best of our knowledge, compiled from publicly available sources and regulatory documents. However, GlobalRareMeds does not guarantee the accuracy, completeness, or timeliness of this information. We strongly recommend that all medical decisions, including usage and dosage, be made only in consultation with the prescribing doctor. GlobalRareMeds assumes no responsibility for consequences arising from reliance on this information without appropriate medical guidance
